What You Need to Know
- Wakely analysts believe the Inflation Reduction Act will cap base drug coverage premium increases at 6% at the plan level.
- CMS quality rating cuts to reduce Medicare Advantage plan revenue by more than 1%.
- Insurers say the proposed 2024 program rules look complicated.
The new Inflation Reduction Act of 2022 will limit annual increases in clients’ share of Medicare Part D prescription drug plan costs, according to officials at the Centers for Medicare and Medicaid Services.
CMS officials are talking about the inflation law provision in the advance notice for the Medicare Advantage program bidding process for 2024.
CMS have also predicted that payment rule changes now under development could hold Medicare Advantage plan issuers’ average change in revenue to a 1.03% increase.
What It Means
CMS and health insurers seem to have moved away from the truce that prevailed while the COVID-19 pandemic was filling hospitals.
The Notice
The new notice will shape bargaining between CMS and insurers over Medicare Advantage coverage prices.
About 30 million of the 65 million Medicare enrollees now use the program to fill in the many gaps in Original Medicare coverage.
CMS is putting the advance notice through a comment period that will end on March 3.
Drug Coverage Costs
CMS usually calculates the Medicare Part D drug plan base beneficiary premium after the bidding process is over, using the bids to determine determining the enrollees’ share of the cost.
CMS uses the base beneficiary premium to calculate the premium imposed on late drug coverage enrollees.
The 2023 base beneficiary premium is $32.74 per month.